profit from every A$100 of sales.
A$0A$100
Artrya
A$3.48-0.57% today
-1.7% in 1 year
1-year low A$2.451-year high A$6.27
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Artrya vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from A$100 of sales | Sales growth a year | Price per A$1 of profit |
|---|---|---|---|
| Artrya | No profit yet | ||
 Veeva Systems | 54.6× · Expensive | ||
 Pro Medicus | 186.3× · Very expensive | ||
 Hinge Health | No profit yet | ||
 M3 | 31.8× · Expensive |
AI analysis
An AI analyst reads Artrya's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of AUD | 2025 |
|---|---|
| 0 | |
| 0 | |
| -22 | |
| -21 | |
| -16 | |
| -0.18 | |
| 100.0% | |
| -78,864.3% | |
| -58,592.9% |
Balance sheet
| In millions of AUD | 2025 |
|---|---|
| Total assets | 24 |
| Cash | 11 |
| Total debt | 1 |
| Total liabilities | 2 |
| 21 | |
| 92 | |
| -70.5% | |
| -77.1% |
Cash flow
| In millions of AUD | 2025 |
|---|---|
| – | |
| 0 | |
| -15 | |
| Dividends paid | – |
| 1 | |
| – |
Valuation
- –
- –
- –
- 35.7×
- 20,388.0×
- –
- –
- -2.5%
- -2.9%
- –
Profitability
- 100.0%
- -78,864.3%
- -58,592.9%
- –
- -70.5%
- -70.5%
- –
- –
- –
- –
Growth
- –
- –
- –
- –
- +11.7%
Financial health
- -0.5×
- 0.03
- –
- –
- 8.27
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 3%of 948
Bottom 28%of 985
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/6Passes 0 of 6. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
45No pass
Benjamin Graham
42No pass
Philip Fisher
56No pass
Peter Lynch
–Not enough data
Joel Greenblatt
2No pass
Charlie Munger
56No pass
Terry Smith
52No pass
Questions about Artrya
Is Artrya a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 6 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Artrya AI analysis
What does Artrya do?
Artrya Limited, a medical technology company, engages in the development and commercialization of artificial intelligence platform that detects, diagnoses, and address coronary artery disease in Australia. It is in Health Information Services, based in West Perth, WA, Australia.
Is Artrya stock halal?
Yes. Artrya passes our halal screen: its business is permitted and its debt is 0.1% of its market value, under the 30% limit. How we check
How has Artrya stock done over the past year?
Down 1.7% over the past twelve months, to A$3.48. It traded between A$2.45 and A$6.27 and is 44.5% below its high.
Who are Artrya's competitors?
The largest listed companies in the same industry are Veeva Systems, Pro Medicus, Hinge Health and M3. The peers table on this page compares their profit, growth and price with Artrya's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.